{"id":190,"date":"2018-12-15T02:47:24","date_gmt":"2018-12-15T10:47:24","guid":{"rendered":"http:\/\/kinaseinhibitorlibrary.com\/?p=190"},"modified":"2022-01-13T16:31:48","modified_gmt":"2022-01-13T09:31:48","slug":"terminal-sialylated-structures-concomitantly-observed-alterations-cellular-morphology","status":"publish","type":"post","link":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/2018\/12\/15\/terminal-sialylated-structures-concomitantly-observed-alterations-cellular-morphology\/","title":{"rendered":"With terminal sialylated structures was concomitantly observed with alterations in cellular morphology"},"content":{"rendered":"

Interestingly, we have further demonstrated that E-cadherin is a carrier of sialylation in the pancreatic cancer cell lines, being a target of modification by the ST3Gal III enzyme. In particular, an increase in a2,3-sialic acid and a decrease in a2,6-sialic acid was shown in the E-cadherin molecule of the ST3Gal III overexpressing cells. This specific modification of E-cadherin with terminal sialylated structures was concomitantly observed with alterations in cellular morphology together with alterations on E-cadherin cellular localization compared with control cells. In addition, these alterations could account for the observed decrease in cell-cell aggregation of the ST3Gal III transfectants together with their increased invasive potential. In PDAC clinical samples. E-cadherin expression was found in some tumor areas, with points of Ecadherin and SLex colocalization where a potential interface between both molecules could exist. In conclusion, we have demonstrated that the alteration of the membrane sialylation pattern of PDAC cells has a modulatory effect in the proper function of important membrane adhesive molecules such as a2b1 integrin and E-cadherin, influencing cell adhesion and invasion processes. In particular, increase in SLex and decrease in a2,6-sialic acid as a consequence of ST3Gal III transfection led to reduced cell-cell adhesiveness, and endowed the cells with a more invasive phenotype. Glycosylation of E-cadherin and a2b1 integrin molecules was also modified as a result of the ST3Gal III transfection, with impact in the modulation of their functions and thus underlying the observed differences in the adhesive and motile phenotype. Specifically, glycan Desloratadine<\/a> changes in a2b1 integrin of ST3Gal III transfected cells were further shown to activate integrin-mediated signaling pathways through FAK phosphorylation and therefore contributing to increase cell migration. Glycosylation of proteins is a key process. Indeed, congenital disorders of glycosylation lead to severe dysfunction and disability. Maturation of glycoproteins in the Golgi apparatus requires hundreds of enzymes, known as AZD7687<\/a> Carbohydrate-Active Enzymes, and also chaperones that act through complex protein-protein interactions.<\/p>\n","protected":false},"excerpt":{"rendered":"

Interestingly, we have further demonstrated that E-cadherin is a carrier of sialylation in the pancreatic cancer cell lines, being a target of modification by the ST3Gal III enzyme. In particular, an increase in a2,3-sialic acid and a decrease in a2,6-sialic acid was shown in the E-cadherin molecule of the ST3Gal III overexpressing cells. This specific … Continue reading With terminal sialylated structures was concomitantly observed with alterations in cellular morphology<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/190"}],"collection":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=190"}],"version-history":[{"count":1,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/190\/revisions"}],"predecessor-version":[{"id":191,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/190\/revisions\/191"}],"wp:attachment":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=190"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}